JPMORGAN CHASE & CO - TRILLIUM THERAPEUTICS INC ownership

TRILLIUM THERAPEUTICS INC's ticker is and the CUSIP is 89620X506. A total of 29 filers reported holding TRILLIUM THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of TRILLIUM THERAPEUTICS INC
ValueSharesWeighting
Q3 2021$26,519,000
+7185.4%
1,510,226
+3921.4%
0.00%
Q2 2021$364,000
-64.1%
37,555
-85.1%
0.00%
Q1 2020$1,015,000
+3174.2%
251,272
+4802.9%
0.00%
Q2 2018$31,000
-18.4%
5,125
-3.2%
0.00%
Q1 2018$38,000
+40.7%
5,293
+10.3%
0.00%
Q4 2016$27,000
-15.6%
4,800
+36.9%
0.00%
Q1 2016$32,0003,5050.00%
Other shareholders
TRILLIUM THERAPEUTICS INC shareholders Q4 2016
NameSharesValueWeighting ↓
AWM Investment Company, Inc. 701,138$4,067,0000.67%
Matrix Capital Management Company, LP 2,288,560$13,274,0000.33%
NEA Management Company, LLC 1,250,000$7,250,0000.31%
Stanley-Laman Group, Ltd. 139,403$809,0000.20%
Cormorant Asset Management, LP 500,000$2,900,0000.19%
Tekla Capital Management LLC 468,399$2,717,0000.10%
Wealth Alliance Advisory Group, LLC 21,800$126,0000.06%
PLATINUM INVESTMENT MANAGEMENT LTD 175,339$1,007,0000.03%
Artal Group S.A. 150,000$870,0000.02%
Baker Brothers Advisors 505,262$2,931,0000.02%
View complete list of TRILLIUM THERAPEUTICS INC shareholders